P1166: REPEAT BIOPSY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A NATIONWIDE SURVEY AND RETROSPECTIVE STUDY

P1166: REPEAT BIOPSY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A NATIONWIDE SURVEY AND RETROSPECTIVE STUDY

Bibliographic Details
Main Authors:	T. Berger, K. R. Geiger, M. Yeshurun, A. Gafter-Gvili, T. Shochat, R. Gurion, P. Raanani, O. Pasvolsky
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847532.79060.a7

Similar Items

P1461: CAR-T VS. STANDARD OF CARE AS SECOND LINE TREATMENT FOR LARGE B CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: L. Shargian, et al.
Published: (2022-06-01)

Effect of steroid treatment on the diagnostic yield of baseline 18f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
by: Karyn Revital Geiger, et al.
Published: (2022-09-01)

P1274: IMPACT OF AUTOLOGOUS TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL TRIPLETS: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: Irina Amitai, et al.
Published: (2023-08-01)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
by: Enver Aydilek, et al.
Published: (2023-09-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)

Maintenance Treatment for Patients With Mantle Cell Lymphoma
by: Liat Vidal, et al.
Published: (2018-08-01)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
by: Jeanne Bohler, et al.
Published: (2022-12-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Shira Buchrits, et al.
Published: (2022-07-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Management of relapsed-refractory diffuse large B cell lymphoma
by: Lalit S Raut, et al.
Published: (2014-01-01)

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Ebru Pekgüç, et al.
Published: (2021-11-01)

Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
by: Elise R. A. Pennings, et al.
Published: (2024-01-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01)

The role of tazemetostat in relapsed/refractory follicular lymphoma
by: Gottfried von Keudell, et al.
Published: (2021-05-01)

Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
by: Tamar Berger, et al.
Published: (2021-06-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by: Leonard Jeff Harris, et al.
Published: (2020-11-01)

A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
by: Jeong-Yeon Cho, et al.
Published: (2024-02-01)

Advances in the treatment of relapsed/refractory marginal zone lymphoma
by: Haotian Wang, et al.
Published: (2024-01-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
by: Robert Stuver, et al.
Published: (2023-01-01)

Treatment selection for patients with relapsed or refractory follicular lymphoma
by: Alan Z. Skarbnik, et al.
Published: (2023-03-01)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
by: S Galimberti, et al.
Published: (2010-06-01)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
by: Bongani Kaimila, et al.
Published: (2017-08-01)

THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA
by: Martin Hutchings
Published: (2014-07-01)

Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
by: Eva Gonzalez Barca
Published: (2023-11-01)

P1161: THERAPY AND OUTCOME IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A CONTEMPORARY AND NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS.
by: Mirian Brink, et al.
Published: (2023-08-01)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
by: Kamel Laribi, et al.
Published: (2022-02-01)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
by: Simon Hallam
Published: (2018-08-01)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
by: Madelyn Burkart, et al.
Published: (2022-03-01)

Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
by: Zachary Braunstein, et al.
Published: (2022-06-01)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
by: Sebastian Kirschey, et al.
Published: (2012-03-01)

Relapsed and/or Refractory Mantle cell Lymphoma: What Role for Temsirolimus?
by: Sebastian Kirschey, et al.
Published: (2012-01-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
by: Denlinger NM, et al.
Published: (2018-03-01)

P578: GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS
by: S. Shimony, et al.
Published: (2022-06-01)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
by: R. Gurion, et al.
Published: (2022-06-01)

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
by: Alejandro Martín García-Sancho, et al.
Published: (2023-12-01)

New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
by: Mattia Schipani, et al.
Published: (2023-12-01)